News | Heart Valve Technology | January 28, 2019

First Tendyne Transcatheter Mitral Valve Implanted in New York

Lenox Hill Hospital implants TMVR system as part of SUMMIT trial

First Tendyne Transcatheter Mitral Valve Implanted in New York

January 28, 2019 — Lenox Hill Hospital is the first hospital in New York City to successfully implant Abbott’s Tendyne transcatheter mitral valve replacement (TMVR) system to replace a leaky heart valve. The procedure was performed as part of a national clinical trial testing the safety and efficacy of the device as an alternative to invasive open heart surgery.

The first patient to have the procedure done at Lenox Hill Hospital, 69-year-old Thomas Furia of Staten Island, N.Y., began to experience severe fatigue and shortness of breath – typical symptoms of a leaky heart valve – earlier in 2018. By April, Furia could not walk more than half a block and had lost consciousness four times. When he sought help, he was turned down by two surgical centers before enrolling in the TMVR trial in August.

Furia’s procedure was performed in October by Chad Kliger, M.D., director of the Structural Heart Disease program at Lenox Hill Hospital. Almost immediately after the procedure, Furia could feel a difference in his ability to breathe and in his energy levels. He is now looking forward to warmer weather, so he can once again ride motorcycles with his wife Carol, a nurse and his caretaker.

The treatment aims to alleviate mitral regurgitation (MR), a debilitating progressive condition in which the failure of the heart’s mitral valve to close tightly during contractions causes blood to flow backward into the heart. The most severe cases of MR often require surgery, as the disorder may lead to serious complications, including arrhythmia, stroke, heart failure and death, if left untreated. MR is the most common valve disease in the United States, affecting about 4 million people, only about 20 percent of whom are eligible for open heart surgery.

The new device presents a novel opportunity for patients who are not surgical candidates — and thus, have limited or no treatment options — to get potentially life-saving therapy without the high risk of open heart surgery. The replacement valve is inserted percutaneously on the side of the chest into a small incision at the tip of the heart. It is then implanted inside the native valve, sealing off any gaps, and stabilized by a tether mechanism. The Tendyne Mitral Valve System is the first and only mitral valve replacement device that can be repositioned and fully retrieved, ensuring precise placement during implantation, which could improve patient outcomes.

“This is potentially a ground-breaking technology that can not only reduce but rather completely obliterate leakiness of the valve, which is quite remarkable and goes a long way in improving a patient’s quality of life,” Kliger said. “It’s an option for patients who previously had limited surgical options or none at all.”

Lenox Hill Hospital is one of two Northwell Health facilities taking part in the TMVR trial. Southside Hospital in Bay Shore, N.Y., was the first in the Northeast to perform the procedure. The clinical trial, officially called SUMMIT, is expected to enroll 1,010 patients at 80 sites across the U.S., Canada and EU to assess the safety and efficacy of the Tendyne TMVR system in treating severe MR.

For more information: www.abbott.com

Related Content

Gallery | Cath Lab | October 31, 2019
This is a photo essay of the interventional cardiology and structural heart technologies on the expo floor and discus
The Alphenix Aero Package from Canon Medical Systems USA, Inc. enables OBLs and ASCs to attain premium technology at a flexible price point by tailoring Canon Medical’s Alphenix systems to fit their facilities’ needs.

The Alphenix Aero Package from Canon Medical Systems USA, Inc. enables OBLs and ASCs to attain premium technology at a flexible price point by tailoring Canon Medical’s Alphenix systems to fit their facilities’ needs.

Technology | Cath Lab | October 28, 2019
Office based labs (OBLs) and ambulatory surgery centers (ASCs) require a fresh perspective from imaging vendors.
Marco Costa, M.D., Ph.D., MBA, president, UH Harrington Heart and Vascular Institute, performing a cath lab procedure.

Marco Costa, M.D., Ph.D., MBA, president, UH Harrington Heart and Vascular Institute, performing a cath lab procedure.

News | Cath Lab | October 28, 2019
October 28, 2019 — Leaders within University Hospitals and the Harrington Heart and Vascular Institute had a vision t
OmniVision Announces Guinness World Record for Smallest Image Sensor

OmniVision's OVM6948 CameraCubeChip, a fully packaged, wafer-level camera module measuring 0.65mm x 0.65mm x 1.158mm, built on OmniVision's OV6948, winner of the Guinness World Record for “The Smallest Image Sensor Commercially Available.”

News | Cath Lab | October 22, 2019
October 22, 2019 — OmniVision Technologies Inc.
People watch the presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., live in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long term surgical outcomes. #TCT2019

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes. 

Feature | Cath Lab | October 03, 2019
October 3, 2019 – Five-year data from the EXCEL Trial showed patients with left main coronary disease treated with pe
Two Stents Implanted in Democratic Presidential Candidate Bernie Sanders, suffers chest pain
News | Cath Lab | October 02, 2019 | Dave Fornell, Editor
October 2, 2019 — Democratic presidential candidate Sen.
Bypass Surgery and Coronary Stenting Yield Comparable 10-Year Survival
News | Cath Lab | September 25, 2019
Ten-year survival rates are similar for bypass surgery and coronary stenting with drug-eluting stents in randomized...
Complete Revascularization Superior to Culprit Lesion-only Intervention
News | Cath Lab | September 10, 2019
An international randomized trial has shown that complete revascularization reduces major cardiovascular events...
The cath lab staff UH Portage Medical Center.

The cath lab staff UH Portage Medical Center.

Feature | Cath Lab | September 09, 2019 | Anjan Gupta, M.D., FACC, FSCAI
Primary percutaneous coronary intervention (PCI) is the preferred treatment for acute...
Overlay Init